Bendamustine salvage for relapsed - refractory multiple myeloma: a retrospective analysis of outcomes in heavily pretreated patients

被引：0
|
作者：
Singh, Aakanksha [1 ]
Agrawal, Narendra [1 ]
Haldar, Rohan [1 ]
Bhurani, Dinesh [1 ]
Raychoudhari, Jyoti Shankar [1 ]
机构：
[1] Rajiv Gandhi Canc Inst & Res Ctr, New Delhi, India
来源：
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2023年 / 23卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P-314
引用
收藏
页码：S211 / S211
页数：1
相关论文
共 50 条
  • [1] Treatment Options for Patients With Heavily Pretreated Relapsed and Refractory Multiple Myeloma
    Dimopoulos, Meletios-Athanasios
    Richardson, Paul
    Lonial, Sagar
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 (07): : 460 - 473
  • [2] Outcomes of Patients with Heavily Pretreated Relapsed/Refractory Multiple Myeloma Receiving Salvage Cytotoxic Therapy with Supportive Stem Cell Boost
    Bangolo, Ayrton
    Oza, Samir
    Reich-Slotky, Ronit
    Chappell, Aimee
    Siegel, David S.
    Parmar, Harsh
    Biran, Noa
    Vesole, David H.
    Phull, Pooja
    CURRENT STEM CELL RESEARCH & THERAPY, 2025, 20 (02) : 211 - 217
  • [3] Outcomes of Patients with Heavily Pretreated Relapsed/Refractory Multiple Myeloma Receiving Salvage Cytotoxic Therapy with Supportive Stem Cell Boost
    Bangolo, Ayrton
    Oza, Samir
    Slotky, Ronit
    Chappell, Aimee
    Siegel, David
    Parmar, Harsh
    Biran, Noa
    Vesole, David H.
    Phull, Pooja
    BLOOD, 2022, 140 : 10041 - 10042
  • [4] Bendamustine in heavily pre-treated patients with relapsed or refractory multiple myeloma
    Stoehr, Elisabeth
    Schmeel, Frederic Carsten
    Schmeel, Leonard Christopher
    Haenel, Mathias
    Schmidt-Wolf, Ingo G. H.
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2015, 141 (12) : 2205 - 2212
  • [5] Bendamustine in heavily pre-treated patients with relapsed or refractory multiple myeloma
    Elisabeth Stöhr
    Frederic Carsten Schmeel
    Leonard Christopher Schmeel
    Mathias Hänel
    Ingo G. H. Schmidt-Wolf
    Journal of Cancer Research and Clinical Oncology, 2015, 141 : 2205 - 2212
  • [6] Bendamustine (B) is associated with low response rates in heavily pretreated relapsed refractory multiple myeloma (RRMM)
    Gahvari, Zhubin
    Schmidt, Timothy
    Brunner, Matthew
    Bergsbaken, Jason
    Callander, Natalie
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S166 - S166
  • [7] Bendamustine in patients with relapsed or refractory multiple myeloma
    M Michael
    I Bruns
    E Bölke
    F Zohren
    A Czibere
    N N Safaian
    F Neumann
    R Haas
    G Kobbe
    R Fenk
    European Journal of Medical Research, 15
  • [8] BENDAMUSTINE IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA
    Michael, M.
    Bruns, I.
    Boelke, E.
    Zohren, F.
    Czibere, A.
    Safaian, N. N.
    Ncumann, F.
    Haas, R.
    Kobbe, G.
    Fenk, R.
    EUROPEAN JOURNAL OF MEDICAL RESEARCH, 2010, 15 (01) : 13 - 19
  • [9] Update on the Treatment of Heavily Pretreated, Relapsed Refractory Multiple Myeloma
    Valdes, Rodriguez
    ONCOLOGY-NEW YORK, 2020, 34 (11): : 504 - 507
  • [10] Melflufen and Dexamethasone in Heavily Pretreated Relapsed and Refractory Multiple Myeloma
    Richardson, Paul G.
    Oriol, Albert
    Larocca, Alessandra
    Blade, Joan
    Cavo, Michele
    Rodriguez-Otero, Paula
    Leleu, Xavier
    Nadeem, Omar
    Hiemenz, John W.
    Hassoun, Hani
    Touzeau, Cyrille
    Alegre, Adrian
    Paner, Agne
    Maisel, Christopher
    Mazumder, Amitabha
    Raptis, Anastasios
    Moreb, Jan S.
    Anderson, Kenneth C.
    Laubach, Jacob P.
    Thuresson, Sara
    Thuresson, Marcus
    Byrne, Catriona
    Harmenberg, Johan
    Bakker, Nicolaas A.
    Mateos, Maria-Victoria
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (07) : 757 - +
12345